patent.fyi
Applications  /  US 2026/0355127
United States Patent Application Publication

US 2026/0355127 A1

Published
Nov 12, 2026
Filed
Jul 9, 2026
Earliest date on the face
Apr 24, 2019
Classification
A61K 9/7053
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Tetracaine as the anesthetic

What ifWhat if tetracaine supplies the local anesthetic activity in the patch?
Claim language“lidocaine or a salt thereof”

A hydrogel reservoir holds dissolved tetracaine hydrochloride and contacts the skin under a flexible backing. Tetracaine released from the reservoir blocks voltage-gated sodium channels in cutaneous sensory nerves.

1.1Acetate buffer controls ph

What ifWhat if an acetic acid and sodium acetate buffer controls lidocaine ionization in a patch formulated without lactic acid?
Claim language“lactic acid”

Acetic acid and sodium acetate set the pH of the aqueous reservoir. Reservoir pH sets the balance between protonated lidocaine in solution and uncharged lidocaine that partitions into the outer skin.

1.1Propylene glycol aids partitioning

What ifWhat if propylene glycol takes the place of the four- to six-carbon hydroxy acid in the lidocaine reservoir?
Claim language“a hydroxy acid having 4 to 6 carbon atoms”

Propylene glycol acts as a cosolvent for lidocaine in the aqueous reservoir. It distributes into the outer skin and changes how lidocaine partitions between the reservoir and the skin.

1.2Low acid silicone matrix

What ifWhat if the patch contains 0.2 moles of lactic acid per mole of lidocaine and uses a silicone adhesive matrix to govern release?
Claim language“0.6 to 1.2 moles per mole”

Lidocaine free base disperses through a silicone pressure-sensitive adhesive coated onto a flexible backing. The adhesive layer thickness and dissolved lidocaine concentration govern diffusion to the skin-facing surface.

1.2Membrane controls reservoir release

What ifWhat if the reservoir contains 1.5 moles of lactic acid per mole of lidocaine and a membrane governs release?
Claim language“0.6 to 1.2 moles per mole”

A sealed aqueous gel reservoir holds the lidocaine formulation behind an ethylene-vinyl acetate membrane. The uncharged fraction partitions into the membrane, and membrane thickness sets the diffusion path to the skin-facing surface.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Patch test for veterinary skin

An ex vivo veterinary permeation test uses a patch containing lidocaine, lactic acid, and malic acid, with 0.9 mole of lactic acid per mole of lidocaine. Excised porcine skin separates the donor and receiver chambers of a diffusion cell, with the patch contacting the outer skin surface and buffered saline contacting the inner surface. Samples collected from the receiver at fixed intervals provide a concentration time profile for calculating cumulative lidocaine permeation per unit area.

Component substitution

Gluconic acid in a hydrogel reservoir

Gluconic acid serves as the six-carbon hydroxy acid in an aqueous hydroxyethyl cellulose gel containing lidocaine hydrochloride and 0.9 mole of lactic acid per mole of lidocaine hydrochloride. The gel fills a cavity between an impermeable backing and a porous polyethylene membrane. An adhesive ring around the cavity holds the membrane against the skin, and dissolved lidocaine diffuses through the membrane during contact.

Parameter or scale variation

Three patch sizes at constant loading

A single coated web contains lidocaine, lactic acid, and malic acid at a ratio of 0.9 mole of lactic acid per mole of lidocaine. A die cuts rectangular patches measuring 20 by 30 mm, 30 by 40 mm, and 40 by 60 mm from the same web. The three sizes have the same coating thickness and lidocaine mass per unit area, so their total lidocaine contents scale in the ratio 1 to 2 to 4.

Segmented coating with flexible gaps

A continuous flexible backing carries a two-by-three array of 10 mm square adhesive islands separated by 2 mm gaps. A stencil deposits the same mixture of lidocaine, lactic acid, and malic acid into each island, with 0.9 mole of lactic acid per mole of lidocaine. A common release liner covers the array during storage, and the uncoated gaps let the backing bend between islands when applied over a curved surface.

Combination with existing systems

Patch integrated with a skin applicator

A disposable cassette holds a backed patch containing lidocaine, lactic acid, and malic acid, with 0.9 mole of lactic acid per mole of lidocaine. The cassette clips into a reusable hand applicator that pulls the release liner around a peel edge as a spring-loaded roller presses the backing toward the skin. Guide rails keep the patch aligned during transfer, and a mechanical stop sets the roller travel to the patch length.

Automated or data-driven variant

Automated control of lactic acid dosing

A batch controller reads the assay and charged mass of lidocaine or its salt and calculates the amount in moles from the molecular weight of the assayed form. The controller uses the assayed concentration of the lactic acid feed to calculate the mass required for a setpoint of 0.9 mole of lactic acid per mole of lidocaine or its salt. A metering pump adds the acid to the mixing vessel under load-cell feedback, and the controller records the delivered mass before the mixture containing malic acid proceeds to coating.

Specific version of a part

Aqueous lidocaine hydrochloride gel

Lidocaine hydrochloride, lactic acid and malic acid dissolve in the water phase of the patch. Hydroxyethylcellulose thickens the solution into a gel supported by a flexible backing.

Tartaric acid in hydrogel

Tartaric acid supplies a four-carbon hydroxy acid in a water and glycerol gel. The gel holds tartaric acid, lactic acid and lidocaine in the skin-contact layer.

One to one molar ratio

The formulation contains 1.00 mole of lactic acid per mole of lidocaine free base. Each gram of lidocaine free base corresponds to about 0.384 grams of pure lactic acid, with the solution mass adjusted for its lactic acid concentration.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2010/0234471 A1
Published
Sep 16, 2010
Filed
Nov 10, 2008
Class
A61K 31/167
Document BUS 2013/0184351 A1
Published
Jul 18, 2013
Filed
Dec 20, 2012
Class
A61K 31/167
Claim 1
Document A
Document B
1.1lidocaine or a salt thereof, lactic acid and a hydroxy acid having 4 to 6 carbon atoms
[7] The lidocaine-containing nonaqueous tape preparation according to any of items [1] to [6], further comprising an organic acid. [8] The lidocaine-containing nonaqueous tape preparation according to any of items [1] to [7], wherein lidocaine and lactic acid are contained in equimolar amounts.
A · US 2010/0234471 A1 · ¶ 12
In another embodiment, lidocaine active ingredients can be formulated as neutralized pharmaceutically acceptable salt forms. Pharmaceutically acceptable salts include the acid addition salts, which are formed with inorganic acids such as, for example, hydrochloric, sulfuric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, citric and the like.
B · US 2013/0184351 A1 · ¶ 103
1.2wherein the amount of lactic acid is 0.6 to 1.2 moles per mole of lidocaine or a salt thereof.
A lidocaine-containing nonaqueous tape preparation comprising a lactic acid salt of lidocaine, wherein the tape preparation comprises: (1) 10 to 40 w/w % of lidocaine, (2) lactic acid in a molar amount 0.6 to 1.2 fold that of lidocaine, and (3) propylene carbonate and/or N-methyl-2-pyrrolidone.
A · US 2010/0234471 A1 · claim 1

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, a high lidocaine content of about 20% by weight leads to the precipitation of a lidocaine crystal in a base of the preparation.
A · US 2010/0234471 A1 · ¶ 3
An object of the present invention is to provide a lidocaine-containing transdermal absorption tape preparation in which lidocaine is present in a state uniformly compatibilized with or dispersed in the base without causing the precipitation of a lidocaine crystal even when lidocaine is present in a high concentration in the preparation.
A · US 2010/0234471 A1 · ¶ 6
This invention is directed to a transdermal delivery patch comprising a local analgesic agent and optionally a permeation enhancement agent, for reducing pain.
B · US 2013/0184351 A1 · ¶ 2
In addition, neuropathic pain is often resistant to available drug therapies; a hallmark of neuropathic pain is its intractability.
B · US 2013/0184351 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355127 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355127/, SHA-256 68f6f580e70f5f478dff7eff7b482330da12fc8e7e22d36177999270d508939c
First published
Permanent addresshttps://patent.fyi/US20260355127/
Content fingerprint (SHA-256)68f6f580e70f5f478dff7eff7b482330da12fc8e7e22d36177999270d508939c
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi